- Home
- IHRT vs ATYR Comparison
IHRT vs ATYR Comparison
Compare IHRT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHRT
- ATYR
- Stock Information
- Founded
- IHRT 1974
- ATYR 2005
- Country
- IHRT United States
- ATYR United States
- Employees
- IHRT N/A
- ATYR N/A
- Industry
- IHRT Broadcasting
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHRT Consumer Discretionary
- ATYR Health Care
- Exchange
- IHRT Nasdaq
- ATYR Nasdaq
- Market Cap
- IHRT N/A
- ATYR 290.6M
- IPO Year
- IHRT 2019
- ATYR 2015
- Fundamental
- Price
- IHRT $1.21
- ATYR $3.34
- Analyst Decision
- IHRT Buy
- ATYR Strong Buy
- Analyst Count
- IHRT 3
- ATYR 6
- Target Price
- IHRT $2.83
- ATYR $18.60
- AVG Volume (30 Days)
- IHRT 598.4K
- ATYR 1.1M
- Earning Date
- IHRT 05-12-2025
- ATYR 05-07-2025
- Dividend Yield
- IHRT N/A
- ATYR N/A
- EPS Growth
- IHRT N/A
- ATYR N/A
- EPS
- IHRT N/A
- ATYR N/A
- Revenue
- IHRT $3,854,532,000.00
- ATYR N/A
- Revenue This Year
- IHRT $0.97
- ATYR $551.06
- Revenue Next Year
- IHRT $5.09
- ATYR $2,144.84
- P/E Ratio
- IHRT N/A
- ATYR N/A
- Revenue Growth
- IHRT 2.76
- ATYR N/A
- 52 Week Low
- IHRT $0.81
- ATYR $1.42
- 52 Week High
- IHRT $2.84
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- IHRT 51.94
- ATYR 51.21
- Support Level
- IHRT $1.02
- ATYR $3.06
- Resistance Level
- IHRT $1.09
- ATYR $3.67
- Average True Range (ATR)
- IHRT 0.08
- ATYR 0.25
- MACD
- IHRT 0.04
- ATYR 0.01
- Stochastic Oscillator
- IHRT 86.67
- ATYR 46.77
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.